In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary disease (COPD) medications, but you didn't tell us how to properly use them. I'd ...

In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary disease (COPD) medications, but you didn’t tell us how to properly use them. I’d ...

In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary ...

Allied Market Research published a report, titled, 'Respiratory Inhaler Devices Market by Product (Metered Dose Inhalers, Dry ...

Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma ...

Cold air can irritate the airways that carry air into the lungs, potentially causing symptoms like coughing, chest tightness, and trouble breathing.

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got ...

The toxic haze that blanketed large parts of India in November didn't just cloud the skies—it pushed sales of asthma and COPD medicines to their highest levels in three years.

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...

Cipla has launched Afrezza, an inhaled insulin powder, offering a needle-free alternative to traditional injectable insulin therapy for diabetes patients.

An update from Therma Bright ( ($TSE:THRM) ) is now available. Therma Bright’s investee company InStatin has sharpened its strategic focus by ...